Cagrilintide
InvestigationalAlso known as: AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
Research Statistics
Novo Nordisk Phase 3 amylin analog with large multi-country trials and clear amylin-receptor mechanism.
Research Dossier
Overview
What is Cagrilintide and what does the research say?
Mechanism of Action
Cagrilintide is a long-acting amylin analog that acts through distinct and complementary pathways to GLP-1 agonists. Human clinical trial data supports its efficacy for weight management.
How It Works (Simplified)
Cagrilintide mimics amylin, a hormone co-secreted with insulin that signals satiety through different brain pathways than GLP-1:
Activates amylin receptors in the area postrema, sending powerful “full” signals to the brain through a different pathway than GLP-1.
Restores responsiveness to leptin, the body’s natural “stop eating” hormone that becomes impaired in obesity.
Delays gastric emptying, prolonging feelings of fullness and preventing rapid blood sugar spikes after meals.
Scientific Pathways
Amylin Receptor Signaling (Satiety)
Cagrilintide → AMY1/2/3 receptors (area postrema) → cAMP signaling → Satiety neurons
↓
Reduced food intakeLeptin Sensitization Pathway (Metabolic)
Cagrilintide → Amylin receptor activation → Hypothalamic circuits → Restored leptin responsivenessKey Research: Lau DCW et al. (2021) demonstrated -10.8% weight loss with cagrilintide 4.5 mg monotherapy in Phase 2 RCT. PMID:34798060
Important Limitations
- Cagrilintide is an investigational compound with no regulatory approvals
- All efficacy data from Phase 1b and Phase 2 trials; Phase 3 results pending
- No long-term safety data beyond 1 year
- No cardiovascular outcomes data (REDEFINE CVOT ongoing, results 2029)
- All clinical trials sponsored by Novo Nordisk (developer)
- Not available outside of clinical trials as of January 2026
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial titration period with dose escalation. Appetite suppression begins within days. GI side effects (nausea, vomiting) most common during this phase. Weight loss typically begins but is modest during titration.
Continued weight loss as maintenance dose is reached. Mean weight loss of approximately 5-7% expected by week 12 based on Phase 2 trajectory. GI side effects typically improve after titration completion.
Ongoing weight loss approaching plateau. Phase 2 monotherapy showed -10.8% at 26 weeks with cagrilintide 4.5 mg. Combination with semaglutide showed -17.1% at 20 weeks, projecting to greater efficacy with longer treatment.
Long-term maintenance phase. Phase 3 trials (REDEFINE) are 68 weeks duration. Weight loss plateau expected around week 40-68 based on GLP-1 agonist class data. Long-term efficacy and durability under investigation.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Cagrilintide product quality
Good Signs (5 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Cagrilintide with other peptides. Based on published research and mechanistic considerations.
Semaglutide
SynergisticCagriSema is the combination product of cagrilintide + semaglutide. Phase 2 data shows -15.6% weight loss vs -5.1% for semaglutide alone. Complementary mechanisms via amylin and GLP-1 pathways.
Liraglutide
CompatibleCagrilintide monotherapy showed comparable efficacy to liraglutide 3.0 mg in Phase 2. No specific interaction data but both can reduce appetite and slow gastric emptying.
Tirzepatide
CautionBoth are potent weight loss agents targeting distinct pathways. No combination studies exist. Concurrent use would have unknown safety profile and unclear benefit given overlapping GLP-1 receptor activity.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cagrilintide
Cagrilintide Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Liraglutide
Victoza, Saxenda, NN2211
The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.